Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1982 Jul;22(1):94–102. doi: 10.1128/aac.22.1.94

Single- and multiple-dose pharmacokinetics of moxalactam in normal subjects.

K S Israel, H R Black, G L Brier, J D Wolny, K A DeSante
PMCID: PMC183680  PMID: 6214998

Abstract

The pharmacokinetics of moxalactam were studied in 86 normal adult male volunteers who received single or multiple doses intravenously or intramuscularly. The short absorption half-times and lag times indicate that the intramuscular dose is rapidly absorbed. The mean plasma half-life was 1.85 +/- 0.24 h for intravenous doses and 2.24 +/- 0.44 h for intramuscular doses. The mean renal clearances for intravenous doses were 0.052 and 0.067 liters/kg per h for intramuscular doses. Although moxalactam is eliminated primarily by the kidney a chromatogram of the feces from volunteers who received multiple doses showed that it is also excreted as the parent compound in to the feces via the biliary tract. The pharmacokinetics parameters of moxalactam when administered intravenously or intramuscularly in single and multiple doses clearly show the kinetics of moxalactam are linear over the dosage ranges studied and are independent of dose.

Full text

PDF
94

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barza M., Tally F. P., Jacobus N. V., Gorbach S. L. In vitro activity of LY127935. Antimicrob Agents Chemother. 1979 Sep;16(3):287–292. doi: 10.1128/aac.16.3.287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bolton W. K., Scheld W. M., Spyker D. A., Overby T. L., Sande M. A. Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction. Antimicrob Agents Chemother. 1980 Dec;18(6):933–938. doi: 10.1128/aac.18.6.933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brogard J. M., Comte F., Pinget M. Pharmacokinetics of cephalosporin antibiotics. Antibiot Chemother (1971) 1978;25:123–162. doi: 10.1159/000401060. [DOI] [PubMed] [Google Scholar]
  4. Buening M. K., Wold J. S., Israel K. S., Krammer R. B. Disulfiram-like reaction to beta-lactams. JAMA. 1981 May 22;245(20):2027–2027. [PubMed] [Google Scholar]
  5. DeSante K. A., Israel K. S., Brier G. L., Wolny J. D., Hatcher B. L. Effect of probenecid on the pharmacokinetics of moxalactam. Antimicrob Agents Chemother. 1982 Jan;21(1):58–61. doi: 10.1128/aac.21.1.58. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Estey E. H., Weaver S. S., Ho D. H., Bodey G. P. Clinical pharmacology of moxalactam in patients with malignant disease. Antimicrob Agents Chemother. 1981 Apr;19(4):639–644. doi: 10.1128/aac.19.4.639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fass R. J. In vitro activity of LY127935. Antimicrob Agents Chemother. 1979 Oct;16(4):503–509. doi: 10.1128/aac.16.4.503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Flournoy D. J., Perryman F. A. LY127935, a new beta-lactam antibiotic, versus Proteus, Klebsiella, Serratia, and Pseudomonas. Antimicrob Agents Chemother. 1979 Nov;16(5):641–643. doi: 10.1128/aac.16.5.641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fu K. P., Aswapokee P., Ho I., Matthijssen C., Neu H. C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother. 1979 Nov;16(5):592–597. doi: 10.1128/aac.16.5.592. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Martinez O. V., Levi J. U., Livingstone A., Malinin T. I., Zeppa R., Hutson D., Einhorn N. Biliary excretion of moxalactam. Antimicrob Agents Chemother. 1981 Aug;20(2):231–234. doi: 10.1128/aac.20.2.231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Neu H. C., Aswapokee N., Fu K. P., Aswapokee P. Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds. Antimicrob Agents Chemother. 1979 Aug;16(2):141–149. doi: 10.1128/aac.16.2.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Neu H. C., Prince A. S. Interaction between moxalactam and alcohol. Lancet. 1980 Jun 28;1(8183):1422–1422. doi: 10.1016/s0140-6736(80)92693-8. [DOI] [PubMed] [Google Scholar]
  13. Newburger J., Wagner J. G., Stavchansky S. A method to predict infinity values for biexponential processes. J Pharmacokinet Biopharm. 1979 Aug;7(4):417–425. doi: 10.1007/BF01062539. [DOI] [PubMed] [Google Scholar]
  14. Parsons J. N., Romano J. M., Levison M. E. Pharmacology of a new 1-oxa-beta-lactam (LY127935) in normal volunteers. Antimicrob Agents Chemother. 1980 Feb;17(2):226–228. doi: 10.1128/aac.17.2.226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Scheld W. M., Spyker D. A., Donowitz G. R., Bolton W. K., Sande M. A. Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects. Antimicrob Agents Chemother. 1981 Apr;19(4):613–619. doi: 10.1128/aac.19.4.613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Schrogie J. J., Rogers J. D., Yeh K. C., Davies R. O., Holmes G. I., Skeggs H., Martin C. M. Pharmacokinetics and comparative pharmacology of cefoxitin and cephalosporins. Rev Infect Dis. 1979 Jan-Feb;1(1):90–98. doi: 10.1093/clinids/1.1.90. [DOI] [PubMed] [Google Scholar]
  17. Sedman A. J., Wagner J. G. CSTRIP, a fortran IV computer program for obtaining initial polyexponential parameter estimates. J Pharm Sci. 1976 Jul;65(7):1006–1010. doi: 10.1002/jps.2600650713. [DOI] [PubMed] [Google Scholar]
  18. Srinivasan S., Francke E. L., Neu H. C. Comparative pharmacokinetics of cefoperazone and cefamandole. Antimicrob Agents Chemother. 1981 Feb;19(2):298–301. doi: 10.1128/aac.19.2.298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Srinivasan S., Fu K. P., Neu H. C. Pharmacokinetics of moxalactam and cefazolin compared in normal volunteers. Antimicrob Agents Chemother. 1981 Feb;19(2):302–305. doi: 10.1128/aac.19.2.302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Trager G. M., White G. W., Zimelis V. M., Panwalker A. P. LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity. Antimicrob Agents Chemother. 1979 Sep;16(3):297–300. doi: 10.1128/aac.16.3.297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Wagner J. G. Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data. J Pharmacokinet Biopharm. 1976 Oct;4(5):443–467. doi: 10.1007/BF01062831. [DOI] [PubMed] [Google Scholar]
  22. Wise R., Andrews J. M., Bedford K. A. LY127935, a novel oxa-beta-lactam: an in vitro comparison with other beta-lactam antibiotics. Antimicrob Agents Chemother. 1979 Sep;16(3):341–345. doi: 10.1128/aac.16.3.341. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Wise R., Baker S., Livingston R. Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels. Antimicrob Agents Chemother. 1980 Sep;18(3):369–371. doi: 10.1128/aac.18.3.369. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES